Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc.

CGEM·NASDAQ

$15.21

-0.85%
HealthcareMedical - Pharmaceuticals

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

At a Glance

Live Snapshot
Market Cap$934.78M
EPS-3.7200
P/E Ratio-4.09
Earnings Date08/06/2026

cgem

Other Current Liabilities

Last Annual Value

36.12M

3-Year CAGR

164%

5-Year CAGR

83%

10-Year CAGR

105%

Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Competitors Analysis of Other Current Liabilities

CGEM · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
36.12M
66.0%59.0%N/A 
49.30M
19.9%5.7%N/A
CBLL logo
CeriBell, Inc.
NASDAQ:CBLL
15.25M
59.9%N/AN/A
EHAB logo
Enhabit, Inc.
NYSE:EHAB
82.20M
26.4%27.1%N/A
58.46M
69.3%46.5%16.8%
28.79M
41.6%28.8%N/A
6.78M
-5.0%18.3%N/A
48.79M
N/A67.4%18.9%
Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. Fair Value Envelope

CGEM · NASDAQ

Our analysis suggests that CGEM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $15.21, this represents a potential HIDDEN relative to our calculated worth for Cullinan Therapeutics, Inc..

Intrinsic Value
Current Price: $15.21